RxDoctor Payments Data

Carole Rojas, MD

Internal Medicine · Lakewood, OHNPI 1265425110

Payments from drug & device makers

$1,942in general payments, 2019–2025

Across 159 payments — averaging $12.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$306
  • Novo Nordisk$234
  • GSK$229
  • Lilly USA, LLC$188
  • Amgen$107
  • Merck$94
  • plus $784 from 15 others

What the payments were for

  • Food & beverage$1,934100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,942 in reported general payments places this provider in the 80th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$53,735
Medicare patients
208
Services billed
780

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban231$144,545
Humira(Cf) PenAdalimumab12$83,496
TrulicityDulaglutide65$74,855
JardianceEmpagliflozin66$57,137
JanuviaSitagliptin Phosphate50$36,430
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$32,775
OzempicSemaglutide27$27,622
FarxigaDapagliflozin Propanediol47$24,793
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr37$23,464
EntrestoSacubitril/Valsartan11$21,073
MounjaroTirzepatide16$15,864
Breo ElliptaFluticasone/Vilanterol21$12,854
XareltoRivaroxaban16$8,633
MyrbetriqMirabegron11$8,261
Incruse ElliptaUmeclidinium Bromide19$8,042

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$90$144,545231 claims
Lilly USA, LLCTrulicity, Mounjaro$188$90,71981 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta$229$77,136112 claims
Boehringer IngelheimJardiance$64$57,13766 claims
MerckJanuvia, Dulera$94$42,23665 claims
Novo NordiskOzempic$234$27,62227 claims
AstraZenecaFarxiga$306$24,79347 claims
NovartisEntresto$18$21,07311 claims
Johnson & JohnsonXarelto$39$8,63316 claims
Astellas Pharma US IncMyrbetriq$50$8,26111 claims
AbbVieSynthroid$89$1,78229 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Lakewood

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →